Virginia Beach, VA - January 13, 2006 - Urologist Gregg Eure, M.D. is starting a unique clinical trial involving the prostate drug Avodart and laser prostate reduction surgery performed at Sentara hospitals.
GlaxoSmithKline, maker of Avodart (dutasteride), is funding the research, which was initiated and written by Urology of Virginia/Devine Tidewater Urology.
"The purpose of the trial is to see if combining the two therapies will improve outcomes," says Dr. Eure. "We want to know if it makes the procedure easier to perform, shortens recovery times or improves patients quality of life after surgery."
The trial with 60 patients will involve a three-month run-up to surgery with half the patients receiving Avodart and the other half placebo. All patients will then receive prostate reduction surgery using the Laserscope GreenLight vaporization technique, which removes benign enlarged prostate tissue to restore urine flow. The drug trial with Avodart and placebo will then continue for one year.
Benign Prostate Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, common in men as they age, which puts pressure on the urethra and constricts urine flow, making it difficult to empty the bladder completely during urination. BPH can lead to frequent bathroom trips, lost sleep and urinary discomfort.
"We are the only site in the country doing this study," says Dr. Eure. "It's an exciting study with real potential to help improve patients lives."